NEW YORK, Jan. 7 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on development of disease ...
Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease ...
NEW YORK, Oct. 27, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major ...
NEW YORK, March 8, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major ...
Intellect Neurosciences, Inc. Receives Notice of Allowance for Alzheimer Monoclonal Antibody Patent from the United States Patent and Trademark Office NEW YORK, June 3, 2010 (GLOBE NEWSWIRE) -- ...
NEW YORK, Nov. 11 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on development of disease ...
NEW YORK, NY--(Marketwired - March 30, 2016) - Intellect Neurosciences, Inc. (ILNS), a research-based biotechnology company focused on the discovery, development and licensing of novel ...
Agreement Follows Recent Grant by Intellect of License to Wyeth (NYSE: WYE) and Elan Pharma International Ltd. NEW YORK, Oct. 8 /PRNewswire-FirstCall/ -- Intellect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback